Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma

被引：1

作者：

Okada, Takuro ^{[1
]}

Fushimi, Chihiro ^{[2
]}

Matsuki, Takashi ^{[3
]}

Okamoto, Isaku ^{[1
]}

Sato, Hiroki ^{[1
]}

Kondo, Takahito ^{[4
]}

Tokashiki, Kunihiko ^{[1
]}

Kishida, Takuma ^{[1
]}

Ito, Tatsuya ^{[1
]}

Yamashita, Gai ^{[1
]}

Aihara, Yusuke ^{[4
]}

Hanyu, Kenji ^{[2
]}

Kushihashi, Yukiomi ^{[2
]}

Masubuchi, Tatsuo ^{[2
]}

Tada, Yuichiro ^{[2
]}

Miura, Kouki ^{[2
]}

Harada, Yuki ^{[3
]}

Momiyama, Kaho ^{[3
]}

Yamashita, Taku ^{[3
]}

Omura, G. O. ^{[5
]}

Takahashi, Hideaki ^{[6
]}

Oridate, Nobuhiko ^{[6
]}

Tsukahara, Kiyoaki ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan

[2] Int Univ Hlth & Welf, Dept Head & Neck Oncol & Surg, Mita Hosp, Tokyo, Japan

[3] Kitasato Univ, Dept Otorhinolaryngol Head & Neck Surg, Sch Med, Sagamihara, Kanagawa, Japan

[4] Tokyo Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Hachioji Med Ctr, Tokyo, Japan

[5] Natl Canc Ctr, Dept Head & Neck Oncol, Tokyo, Japan

[6] Yokohama City Univ, Dept Otorhinolaryngol Head & Neck Surg, Yokohama, Kanagawa, Japan

来源：

ANTICANCER RESEARCH | 2022年 / 42卷 / 03期

关键词：

Squamous cell carcinoma; head and neck; nivolumab; WEIGHT-LOSS; CANCER; HEAD; CHEMOTHERAPY; NEUTROPHILS; ESOPHAGEAL; PLATELETS; CETUXIMAB; RATIO;

D O I：

10.21873/anticanres.15635

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.

引用

页码：1607 / 1613

页数：7

共 50 条

[1] Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma
Sato, Hiroki
Fushimi, Chihiro
Okada, Takuro
Matsuki, Takashi
Kondo, Takahito
Omura, G. O.
Miura, Kouki
Yamashita, Taku
Okamoto, Isaku
Tsukahara, Kiyoaki
[J]. IN VIVO, 2020, 34 (05): : 2967 - 2972
[2] Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study
Kondo, Takahito
Okamoto, Isaku
Sato, Hiroki
Koyama, Nobuyuki
Fushimi, Chihiro
Okada, Takuro
Masubuchi, Tatsuo
Miura, Kouki
Matsuki, Takashi
Yamashita, Taku
Omura, Go
Takahashi, Hideaki
Tsukahara, Kiyoaki
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 340 - 347
[3] Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Ferris, Robert L.
Licitra, Lisa
Fayette, Jerome
Even, Caroline
Blumenschein, George, Jr.
Harrington, Kevin J.
Guigay, Joel
Vokes, Everett E.
Saba, Nabil F.
Haddad, Robert
Ramkumar, Shanmugasundaram
Russell, Jeffery
Brossart, Peter
Tahara, Makoto
Colevas, A. Dimitrios
Concha-Benavente, Fernando
Lynch, Mark
Li, Li
Gillison, Maura L.
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (17) : 5221 - 5230
[4] Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma
Ikeda, Go
Miyakoshi, Jun
Yamamoto, Shun
Kato, Ken
[J]. FUTURE ONCOLOGY, 2024, 20 (11) : 665 - 677
[5] Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy
Motoo Nomura
Taisuke Hosokai
Masashi Tamaoki
Akira Yokoyama
Shigemi Matsumoto
Manabu Muto
[J]. Esophagus, 2023, 20 : 722 - 731
[6] Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy
Nomura, Motoo
Hosokai, Taisuke
Tamaoki, Masashi
Yokoyama, Akira
Matsumoto, Shigemi
Muto, Manabu
[J]. ESOPHAGUS, 2023, 20 (04) : 722 - 731
[7] Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Yamashita, G. A., I
Okamoto, I. S. A. K. U.
Ito, T. A. T. S. U. Y. A.
Tokashiki, K. U. N. I. H. I. K. O.
Okada, T. A. K. U. R. O.
Tsukahara, K. I. Y. O. A. K. I.
[J]. ANTICANCER RESEARCH, 2023, 43 (08) : 3679 - 3683
[8] Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient
Kondo, Takahito
Kawachi, Shigeyuki
Nakatsugawa, Munehide
Takeda, Atsuo
Kikawada, Naiue
Aihara, Yusuke
Okimura, Akira
Hirano, Hiroshi
Ogawa, Yasuo
Tsukahara, Kiyoaki
[J]. AURIS NASUS LARYNX, 2022, 49 (04) : 721 - 726
[9] Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma
Yamakawa, Nobuhiro
Umeda, Masahiro
Yoshii, Yumi
Mitsudo, Kenji
Noguchi, Makoto
Kusukawa, Jingo
Katakura, Akira
Nakayama, Hideki
Sasaki, Masashi
Noguchi, Tadahide
Ueda, Michihiro
Bukawa, Hiroki
Yagihara, Kazuhiro
Horie, Akihisa
Miyazaki, Akihiro
Chikazu, Daichi
Tomihara, Kei
Mishima, Katsuaki
Otsuru, Mitsunobu
Asoda, Seiji
Fujiwara, Shigeyoshi
Ohyama, Yoshio
Kurita, Hiroshi
Kawamata, Hitoshi
Fukuda, Masayuki
Shintani, Yukari
Kobayashi, Takanori
Kanno, Takahiro
Oh-Iwa, Ichiro
Kawano, Kenji
Yamashita, Yoshio
Kobayashi, Wataru
Ohiro, Yoichi
Uzawa, Katsuhiro
Ota, Yoshihide
Kirita, Tadaaki
[J]. ORAL DISEASES, 2024, 30 (02) : 247 - 258
[10] Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
Saba, Nabil F.
Blumenschein, George, Jr.
Guigay, Joel
Licitra, Lisa
Fayette, Jerome
Harrington, Kevin J.
Kiyota, Naomi
Gillison, Maura L.
Ferris, Robert L.
Jayaprakash, Vijayvel
Li, Li
Brossart, Peter
[J]. ORAL ONCOLOGY, 2019, 96 : 7 - 14

← 1 2 3 4 5 →